RU2014106367A - N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ - Google Patents
N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ Download PDFInfo
- Publication number
- RU2014106367A RU2014106367A RU2014106367/04A RU2014106367A RU2014106367A RU 2014106367 A RU2014106367 A RU 2014106367A RU 2014106367/04 A RU2014106367/04 A RU 2014106367/04A RU 2014106367 A RU2014106367 A RU 2014106367A RU 2014106367 A RU2014106367 A RU 2014106367A
- Authority
- RU
- Russia
- Prior art keywords
- imidazolidin
- ylidene
- pyridin
- amine
- hydrogen
- Prior art date
Links
- -1 IMIDAZOLIDIN-2-YLIDENE Chemical class 0.000 title claims abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 25
- 150000001875 compounds Chemical class 0.000 claims abstract 24
- 239000001257 hydrogen Substances 0.000 claims abstract 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 8
- 150000002431 hydrogen Chemical group 0.000 claims abstract 6
- 125000001246 bromo group Chemical group Br* 0.000 claims abstract 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 4
- 229910052736 halogen Chemical group 0.000 claims abstract 4
- 150000002367 halogens Chemical group 0.000 claims abstract 4
- JJBVQVOTIPKSGL-UHFFFAOYSA-N 4-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound C1=NC=2NC=CC=2C(Br)=C1N=C1NCCN1 JJBVQVOTIPKSGL-UHFFFAOYSA-N 0.000 claims abstract 3
- JNYBTRZAIDYYPC-UHFFFAOYSA-N 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound C1=NC=2NC=CC=2C(Cl)=C1N=C1NCCN1 JNYBTRZAIDYYPC-UHFFFAOYSA-N 0.000 claims abstract 3
- RWVAQBIYKRNWEP-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-1-methylpyrrolo[2,3-b]pyridin-5-amine Chemical compound C=1N=C2N(C)C=CC2=CC=1N=C1NCCN1 RWVAQBIYKRNWEP-UHFFFAOYSA-N 0.000 claims abstract 3
- OTUFXGVQGPQPFI-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-1h-imidazo[4,5-b]pyridin-6-amine Chemical compound N1CCNC1=NC1=CN=C(NC=N2)C2=C1 OTUFXGVQGPQPFI-UHFFFAOYSA-N 0.000 claims abstract 3
- MSQQSZNQHSQEJT-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound N1CCNC1=NC1=CN=C(NC=C2)C2=C1 MSQQSZNQHSQEJT-UHFFFAOYSA-N 0.000 claims abstract 3
- GFNBWPYHEUJLIN-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-4-methyl-1h-pyrrolo[2,3-b]pyridin-5-amine Chemical compound C1=NC=2NC=CC=2C(C)=C1NC1=NCCN1 GFNBWPYHEUJLIN-UHFFFAOYSA-N 0.000 claims abstract 3
- HXPULZAEYZUIES-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-[1,3]thiazolo[5,4-b]pyridin-6-amine Chemical compound N1CCN=C1NC1=CN=C(SC=N2)C2=C1 HXPULZAEYZUIES-UHFFFAOYSA-N 0.000 claims abstract 3
- ADEZWLBYWPDFFM-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)furo[2,3-b]pyridin-5-amine Chemical compound N1CCNC1=NC1=CN=C(OC=C2)C2=C1 ADEZWLBYWPDFFM-UHFFFAOYSA-N 0.000 claims abstract 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000036407 pain Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 239000005022 packaging material Substances 0.000 claims 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000033830 Hot Flashes Diseases 0.000 claims 2
- 206010060800 Hot flush Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 206010000496 acne Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 240000005926 Hamelia patens Species 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 208000014692 Lyell syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000003493 Rhinophyma Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010072005 Spinal pain Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 claims 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 claims 1
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009245 menopause Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 231100000046 skin rash Toxicity 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/20—External fittings
- B65D25/205—Means for the attachment of labels, cards, coupons or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mechanical Engineering (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161511372P | 2011-07-25 | 2011-07-25 | |
| US61/511,372 | 2011-07-25 | ||
| PCT/US2012/046161 WO2013015984A1 (en) | 2011-07-25 | 2012-07-11 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014106367A true RU2014106367A (ru) | 2015-08-27 |
Family
ID=46551906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014106367/04A RU2014106367A (ru) | 2011-07-25 | 2012-07-11 | N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8513419B2 (enExample) |
| EP (1) | EP2736906B1 (enExample) |
| JP (1) | JP6052685B2 (enExample) |
| KR (1) | KR20140082643A (enExample) |
| CN (1) | CN103781785A (enExample) |
| AU (1) | AU2012287338A1 (enExample) |
| BR (1) | BR112014001951A2 (enExample) |
| CA (1) | CA2843245A1 (enExample) |
| IL (1) | IL230653A (enExample) |
| MX (1) | MX336578B (enExample) |
| RU (1) | RU2014106367A (enExample) |
| WO (1) | WO2013015984A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2843611B2 (ja) | 1989-09-14 | 1999-01-06 | 中外製薬株式会社 | 水酸基ラジカル消去剤 |
| WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
| RU2715897C2 (ru) | 2015-06-09 | 2020-03-04 | Эббви Инк. | Модуляторы ядерных рецепторов |
| KR200490025Y1 (ko) | 2018-05-11 | 2019-09-11 | 고양시농업기술센터 | 포트의 보관이 가능한 화분기구 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| EP0775134A4 (en) | 1994-08-04 | 1997-08-13 | Synaptic Pharma Corp | NEW BENZIMIDAZOLE DERIVATIVES |
| US5677321A (en) * | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| KR20000069128A (ko) * | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물 |
| WO1998023612A1 (en) * | 1996-11-25 | 1998-06-04 | The Procter & Gamble Company | 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists |
| US5866579A (en) | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
| EP3584237B1 (en) * | 2009-10-06 | 2020-12-09 | Allergan, Inc. | Alpha adrenergic receptor modulators |
-
2012
- 2012-07-11 MX MX2014001060A patent/MX336578B/es unknown
- 2012-07-11 BR BR112014001951A patent/BR112014001951A2/pt not_active IP Right Cessation
- 2012-07-11 RU RU2014106367/04A patent/RU2014106367A/ru not_active Application Discontinuation
- 2012-07-11 CN CN201280043028.2A patent/CN103781785A/zh active Pending
- 2012-07-11 JP JP2014522853A patent/JP6052685B2/ja not_active Expired - Fee Related
- 2012-07-11 KR KR1020147004721A patent/KR20140082643A/ko not_active Withdrawn
- 2012-07-11 WO PCT/US2012/046161 patent/WO2013015984A1/en not_active Ceased
- 2012-07-11 AU AU2012287338A patent/AU2012287338A1/en not_active Abandoned
- 2012-07-11 CA CA2843245A patent/CA2843245A1/en not_active Abandoned
- 2012-07-11 US US13/546,211 patent/US8513419B2/en active Active
- 2012-07-11 EP EP12738322.2A patent/EP2736906B1/en not_active Not-in-force
-
2013
- 2013-07-18 US US13/945,825 patent/US8741921B2/en active Active
-
2014
- 2014-01-26 IL IL230653A patent/IL230653A/en active IP Right Grant
- 2014-04-21 US US14/257,517 patent/US9034896B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013015984A1 (en) | 2013-01-31 |
| US20130324571A1 (en) | 2013-12-05 |
| MX2014001060A (es) | 2014-08-21 |
| CN103781785A (zh) | 2014-05-07 |
| US8513419B2 (en) | 2013-08-20 |
| US20130030014A1 (en) | 2013-01-31 |
| US8741921B2 (en) | 2014-06-03 |
| MX336578B (es) | 2016-01-25 |
| JP6052685B2 (ja) | 2016-12-27 |
| JP2014521642A (ja) | 2014-08-28 |
| IL230653A0 (en) | 2014-03-31 |
| US20140228395A1 (en) | 2014-08-14 |
| US9034896B2 (en) | 2015-05-19 |
| EP2736906B1 (en) | 2016-10-19 |
| EP2736906A1 (en) | 2014-06-04 |
| KR20140082643A (ko) | 2014-07-02 |
| AU2012287338A1 (en) | 2014-02-27 |
| HK1198763A1 (en) | 2015-06-05 |
| BR112014001951A2 (pt) | 2017-02-21 |
| IL230653A (en) | 2016-04-21 |
| CA2843245A1 (en) | 2013-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201038569A (en) | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy | |
| KR102501558B1 (ko) | Shp2의 활성을 억제하기 위한 n-아자스피로시클로알칸 치환된 n-헤테로아릴 화합물 및 조성물 | |
| RU2014106367A (ru) | N-(ИМИДАЗОЛИДИН-2-ИЛИДЕН)-ГЕТЕРОЦИКЛОПЕНТА[b]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ АЛЬФА 2 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| KR102785173B1 (ko) | 벤조티오펜-기반 선택적 에스트로겐 수용체 하향조절제 | |
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| IL271149B2 (en) | Compounds for modulating s1p1 activity and methods of using the same | |
| RU2012134639A (ru) | Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза | |
| RU2015110122A (ru) | Производные имидазолина, способы их получения и их применение в медицине | |
| AR116880A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm | |
| WO2018199166A1 (ja) | 新規テトラヒドロナフチルウレア誘導体 | |
| JP2021534252A (ja) | インテグリンアンタゴニスト | |
| JP2014521642A5 (enExample) | ||
| CA2831025C (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| JP2011509296A (ja) | イオンチャネルリガンドとしてのアミド誘導体およびそれを使用する薬学的組成物および方法 | |
| RU2014106364A (ru) | Производные n-(имидазолидин-2-илидин)хинолина как модуляторы адренергических рецепторов альфа-2 | |
| US7829587B2 (en) | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | |
| JP2014521647A5 (enExample) | ||
| Yusupova | Muscarinic Mechanisms in Emmetropization in the Chick: Evidence for Differences in Form Deprivation Versus Negative Lens-wear | |
| CA3182012A1 (en) | Akt3 modulators | |
| KR20150126689A (ko) | 치환된 벤족사졸 및 이의 사용 방법 | |
| TH167756A (th) | อนุพันธ์ไพริโดนสำหรับการบำบัดการติดเชื้อไวรัสและโรคอื่นเพิ่มเติม |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20180416 |